VYTORIN

This brand name is authorized in United States. It is also authorized in Australia, Brazil, Ecuador, Germany, Hong Kong SAR China, Italy, Mexico, Singapore, Spain.

Active ingredients

The drug VYTORIN contains a combination of these active pharmaceutical ingredients (APIs):

1	Ezetimibe UNII EOR26LQQ24 - EZETIMIBE
	Ezetimibe is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol. The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol.
	Read more about Ezetimibe
2	Simvastatin UNII AGG2FN16EV - SIMVASTATIN
	Simvastatin has a potent activity in inhibiting HMG-CoA reductase (3-hydroxy–3-ethylglutaryl-CoA-reductase). Simvastatin has been shown to reduce both normal and elevated LDL-C concentrations.
	Read more about Simvastatin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VYTORIN Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10BA02	Simvastatin and ezetimibe	C Cardiovascular system → C10 Lipid modifying agents → C10B Lipid modifying agents, combinations → C10BA Combinations of various lipid modifying agents
Discover more medicines within C10BA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8881K, 8882L, 9483D, 9484E
BR	Câmara de Regulação do Mercado de Medicamentos	525503402114214, 525503403110212, 525503404117210, 525503405113219, 525503406111211, 525503407116215, 525516020019403, 525516020019503, 525516020019603
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	15293338, 17309718
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	25.819-08-04, 25.820-08-04, 25.822-08-04
ES	Centro de información online de medicamentos de la AEMPS	66571, PA1286-062-002, PA1286-062-003
HK	Department of Health Drug Office	53014, 53016, 53017
IT	Agenzia del Farmaco	036690067, 036690218, 036690360
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	127M2004
SG	Health Sciences Authority	13011P, 13012P
US	FDA, National Drug Code	55289-280, 55289-520, 66582-311, 66582-312, 66582-313, 66582-315